BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18480687)

  • 1. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension.
    Thase ME; Haight BR; Johnson MC; Hunt T; Krishen A; Fleck RJ; Modell JG
    J Clin Psychopharmacol; 2008 Jun; 28(3):302-7. PubMed ID: 18480687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
    Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
    de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
    Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
    Anderson JW; Greenway FL; Fujioka K; Gadde KM; McKenney J; O'Neil PM
    Obes Res; 2002 Jul; 10(7):633-41. PubMed ID: 12105285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
    Mistry GC; Maes AL; Lasseter KC; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2008 May; 48(5):592-8. PubMed ID: 18353996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sustained-release diltiazem on blood pressure and serum lipids: a multicenter, randomized, placebo-controlled study.
    Djian J; Fermé I; Zannad F; Chaignon M; Asmar R
    J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S38-45. PubMed ID: 1706012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does pseudoephedrine increase blood pressure in patients with controlled hypertension?
    Coates ML; Rembold CM; Farr BM
    J Fam Pract; 1995 Jan; 40(1):22-6. PubMed ID: 7807033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term antihypertensive effect of delayed-action molsidomine].
    Fach WA; Kostanecka T; Kober G
    Z Kardiol; 1994 Sep; 83(9):646-51. PubMed ID: 7801667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.
    Black DW; Arndt S; Coryell WH; Argo T; Forbush KT; Shaw MC; Perry P; Allen J
    J Clin Psychopharmacol; 2007 Apr; 27(2):143-50. PubMed ID: 17414236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
    Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
    Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive efficacy of sustained-release verapamil.
    Zachariah PK; Sheps SG; Oshrain C; Schirger A; Stein WJ
    J Clin Hypertens; 1987 Dec; 3(4):536-46. PubMed ID: 3330987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of sustained-release-L-arginine formulation on blood pressure and vascular compliance in 29 healthy individuals.
    Miller AL
    Altern Med Rev; 2006 Mar; 11(1):23-9. PubMed ID: 16597191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piretanide in the treatment of essential hypertension. A double-blind comparison versus placebo.
    Verho M; Rangoonwala B; Beloso M; Maass L; Bender R; Garduno D
    Drugs Exp Clin Res; 1986; 12(5):385-91. PubMed ID: 3522159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects.
    Kozuma K; Tsuchiya S; Kohori J; Hase T; Tokimitsu I
    Hypertens Res; 2005 Sep; 28(9):711-8. PubMed ID: 16419643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of bupropion on psychomotor performance.
    Paul MA; Gray G; Kenny G; Lange M
    Aviat Space Environ Med; 2002 Nov; 73(11):1094-9. PubMed ID: 12433233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.